State Street’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$261M Buy
826,539
+47,683
+6% +$11.2M 0.01% 885
2026
Q1
$155M Buy
778,856
+27,651
+4% +$5.47M 0.01% 1100
2025
Q4
$142M Buy
751,205
+1,845
+0.2% +$355K ﹤0.01% 1153
2025
Q3
$133M Sell
749,360
-394
-0.1% -$58.6K ﹤0.01% 1180
2025
Q2
$85.2M Buy
749,754
+22,629
+3% +$2.42M ﹤0.01% 1394
2025
Q1
$76.4M Sell
727,125
-16,507
-2% -$1.87M ﹤0.01% 1408
2024
Q4
$79.7M Buy
743,632
+36,218
+5% +$4.09M ﹤0.01% 1481
2024
Q3
$70.8M Buy
707,414
+18,642
+3% +$1.88M ﹤0.01% 1521
2024
Q2
$58M Buy
688,772
+17,488
+3% +$1.39M ﹤0.01% 1587
2024
Q1
$49.1M Buy
671,284
+3,000
+0.4% +$221K ﹤0.01% 1739
2023
Q4
$47.7M Buy
668,284
+45,029
+7% +$2.66M ﹤0.01% 1727
2023
Q3
$37.3M Buy
623,255
+10,643
+2% +$701K ﹤0.01% 1794
2023
Q2
$44.2M Sell
612,612
-32,946
-5% -$2.47M ﹤0.01% 1748
2023
Q1
$47.5M Sell
645,558
-4,356
-0.7% -$310K ﹤0.01% 1682
2022
Q4
$43.4M Sell
649,914
-875,049
-57% -$56.9M ﹤0.01% 1734
2022
Q3
$81.9M Sell
1,524,963
-212,556
-12% -$12.5M 0.01% 1247
2022
Q2
$96.7M Sell
1,737,519
-12,625
-0.7% -$716K 0.01% 1169
2022
Q1
$123M Buy
1,750,144
+327,717
+23% +$23.8M 0.01% 1150
2021
Q4
$137M Sell
1,422,427
-49,468
-3% -$4.57M 0.01% 1060
2021
Q3
$128M Buy
1,471,895
+94,200
+7% +$7.29M 0.01% 1078
2021
Q2
$113M Buy
1,377,695
+122,931
+10% +$10.2M 0.01% 1206
2021
Q1
$119M Sell
1,254,764
-613,356
-33% -$58M 0.01% 1103
2020
Q4
$116M Buy
1,868,120
+310,602
+20% +$17.7M 0.01% 1040
2020
Q3
$92.6M Sell
1,557,518
-61,813
-4% -$4.22M 0.01% 1015
2020
Q2
$113M Sell
1,619,331
-388,840
-19% -$24.7M 0.01% 877
2020
Q1
$91.1M Sell
2,008,171
-1,529
-0.1% -$86.7K 0.01% 904
2019
Q4
$131M Sell
2,009,700
-27,216
-1% -$1.82M 0.01% 881
2019
Q3
$126M Buy
2,036,916
+150,244
+8% +$9.43M 0.01% 868
2019
Q2
$134M Sell
1,886,672
-182,012
-9% -$13.4M 0.01% 863
2019
Q1
$162M Buy
2,068,684
+457,775
+28% +$34.7M 0.01% 746
2018
Q4
$136M Buy
1,610,909
+232,151
+17% +$24.7M 0.01% 754
2018
Q3
$236M Sell
1,378,758
-81,137
-6% -$12.2M 0.02% 648
2018
Q2
$189M Sell
1,459,895
-63,418
-4% -$7.08M 0.02% 713
2018
Q1
$157M Sell
1,523,313
-27,633
-2% -$2.73M 0.01% 780
2017
Q4
$132M Buy
1,550,946
+184,522
+14% +$16M 0.01% 861
2017
Q3
$116M Buy
1,366,424
+65,378
+5% +$5.18M 0.01% 902
2017
Q2
$98.5M Sell
1,301,046
-61,943
-5% -$4.33M 0.01% 972
2017
Q1
$90M Buy
1,362,989
+2,053
+0.2% +$135K 0.01% 1012
2016
Q4
$86.3M Sell
1,360,936
-36,208
-3% -$2.28M 0.01% 981
2016
Q3
$88.9M Buy
1,397,144
+215,728
+18% +$15.8M 0.01% 940
2016
Q2
$87.9M Buy
1,181,416
+59,656
+5% +$4.43M 0.01% 896
2016
Q1
$74.9M Buy
1,121,760
+103,249
+10% +$6.28M 0.01% 965
2015
Q4
$68.9M Buy
1,018,511
+71,779
+8% +$4.43M 0.01% 997
2015
Q3
$50.6M Sell
946,732
-22,645
-2% -$1.37M 0.01% 1167
2015
Q2
$61M Sell
969,377
-68,303
-7% -$3.73M 0.01% 1146
2015
Q1
$49.9M Sell
1,037,680
-34,831
-3% -$1.33M 0.01% 1242
2014
Q4
$35.6M Buy
1,072,511
+34,871
+3% +$1.13M ﹤0.01% 1403
2014
Q3
$30.4M Buy
1,037,640
+120,750
+13% +$4.01M ﹤0.01% 1436
2014
Q2
$35.6M Sell
916,890
-28,032
-3% -$1.14M ﹤0.01% 1406
2014
Q1
$39.6M Sell
944,922
-63,301
-6% -$2.64M ﹤0.01% 1328
2013
Q4
$33.1M Sell
1,008,223
-213,265
-17% -$6.95M ﹤0.01% 1432
2013
Q3
$33M Buy
1,221,488
+403,762
+49% +$11.4M ﹤0.01% 1396
2013
Q2
$19.1M Buy
+817,726
New +$14.7M ﹤0.01% 1658

Other funds holding LGND

State Street's LGND Position: Q2 2026 in Review

State Street increased its Ligand Pharmaceuticals (LGND) stake by 6.1% in Q2 2026, buying an estimated $11.2M and bringing the position to 826,539 shares worth $261M. The position accounts for 0.01% of the portfolio, ranked #885.

State Street first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • State Street held 826,539 shares of Ligand Pharmaceuticals worth $261M as of Q2 2026.
  • State Street bought 47,683 Ligand Pharmaceuticals shares in Q2 2026, an estimated $11.2M.
  • Ligand Pharmaceuticals made up 0.01% of State Street's portfolio in Q2 2026, its #885 holding.
  • State Street first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.